LC–MS‐based plasma metabolomics study of the intervention effect of different polar parts of hawthorn on gastrointestinal motility disorder rats. (1st February 2021)

• Record Type: Journal Article
• Authors: Wang, Kaiyang; Luo, Lan; Xu, Xiaoli; Chen, Xingyu; He, Qiong; Zou, Zhongjie; Wang, Shumei; Liang, Shengwang
• Is Part Of: Biomedical chromatography. Volume 35:Number 6(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-02-01
• Subjects: biomarker -- dyspepsia -- hawthorn -- LC–MS -- metabolomics; Chromatographic analysis -- Periodicals; Biology -- Periodicals; Medicine -- Periodicals; Biology -- Periodicals; Chromatography -- methods -- Periodicals; Medicine -- Periodicals; 543.089
• DOI: 10.1002/bmc.5076
• Languages: English
• ISSNs: 0269-3879

Abstract

Abstract: Dyspepsia, one of the most prevalent diseases of the digestive tract that impacts the quality of patient life, is mainly caused by gastrointestinal motility disorder. Hawthorn is a commonly used traditional Chinese medicine for treating dyspepsia, and has been proven to improve gastrointestinal motility. Herein, a rat model of gastrointestinal motility disorder was established by subcutaneous injection with atropine. The modeled rats were treated with four polar parts (T1–4 in descending polarity, corresponding to water, n ‐butanol, ethyl acetate and petroleum ether extracts, respectively) of hawthorn. Through metabolomics analysis, a total of 20 significantly metabolites were identified with significant changes in their abundance levels and these metabolites were related to many metabolic pathways such as amino acid metabolism and primary bile acid biosynthesis. The results showed that T3 had the best therapeutic effect of promoting gastrointestinal motility. Other parts showed no obvious therapeutic effect, demonstrating that the effective components of hawthorn may be compounds of medium polarity. T3 might achieve good therapeutic effects owing to the gastrointestinal motility promotion activity, and by rectifying the disturbed metabolic pathways in the gastrointestinal motility disorder model.